SAN

75.24

-1.34%↓

UCB

249.3

-0.32%↓

SHL.DE

39.72

-1.63%↓

ARGX

615.4

-0.81%↓

PHIA

24.63

-1.36%↓

SAN

75.24

-1.34%↓

UCB

249.3

-0.32%↓

SHL.DE

39.72

-1.63%↓

ARGX

615.4

-0.81%↓

PHIA

24.63

-1.36%↓

SAN

75.24

-1.34%↓

UCB

249.3

-0.32%↓

SHL.DE

39.72

-1.63%↓

ARGX

615.4

-0.81%↓

PHIA

24.63

-1.36%↓

SAN

75.24

-1.34%↓

UCB

249.3

-0.32%↓

SHL.DE

39.72

-1.63%↓

ARGX

615.4

-0.81%↓

PHIA

24.63

-1.36%↓

SAN

75.24

-1.34%↓

UCB

249.3

-0.32%↓

SHL.DE

39.72

-1.63%↓

ARGX

615.4

-0.81%↓

PHIA

24.63

-1.36%↓

Search

Laboratorios Farmaceuticos Rovi SA

Abrir

SetorSaúde

79.05 -1.74

Visão Geral

Variação de preço das ações

24h

Atual

Mín

77.35

Máximo

80.45

Indicadores-chave

By Trading Economics

Rendimento

-33M

43M

Vendas

7.9M

218M

P/E

Médio do Setor

34.705

66.845

EPS

1.135

Margem de lucro

19.539

Funcionários

2,197

EBITDA

-21M

63M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+11.32% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

230M

4.2B

Abertura anterior

80.79

Fecho anterior

79.05

Sentimento de Notícias

By Acuity

50%

50%

128 / 351 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de mar. de 2026, 19:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Diana Shipping Increases Offer to Acquire Genco -- Update

8 de mar. de 2026, 23:47 UTC

Conversa de Mercado
Notícias Principais

Global Equities Roundup: Market Talk

8 de mar. de 2026, 23:47 UTC

Conversa de Mercado
Notícias Principais

Nikkei May Fall on Higher Energy Prices, Signs of U.S. Econ Weakness -- Market Talk

8 de mar. de 2026, 23:46 UTC

Conversa de Mercado
Notícias Principais

Gold Falls Amid Dollar's Strength -- Market Talk

8 de mar. de 2026, 23:34 UTC

Conversa de Mercado
Notícias Principais

Oil Futures Surge Above $100/bbl Amid Growing Middle East Conflict -- Market Talk

8 de mar. de 2026, 23:08 UTC

Notícias Principais

Front-month WTI Crude Futures Jump 16.6%, Front-Month Brent Crude Futures Climb 15.2%

8 de mar. de 2026, 23:05 UTC

Notícias Principais

Front-month Crude Oil Futures Surge Amid Rising Middle East Conflict

8 de mar. de 2026, 22:37 UTC

Notícias Principais

The Long-Feared Persian Gulf Oil Squeeze Is Upon -2-

8 de mar. de 2026, 22:37 UTC

Notícias Principais

The Long-Feared Persian Gulf Oil Squeeze Is Upon Us -- WSJ

7 de mar. de 2026, 02:30 UTC

Notícias Principais

Iran War Is Kicking India When It's Already Down -- Barrons.com

6 de mar. de 2026, 22:26 UTC

Notícias Principais

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6 de mar. de 2026, 22:07 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6 de mar. de 2026, 22:03 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

6 de mar. de 2026, 22:03 UTC

Conversa de Mercado

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6 de mar. de 2026, 21:50 UTC

Conversa de Mercado
Notícias Principais

Financial Services Roundup: Market Talk

6 de mar. de 2026, 21:37 UTC

Ganhos

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6 de mar. de 2026, 21:25 UTC

Notícias Principais

How The Iran War Impacts Ukraine. -- Barrons.com

6 de mar. de 2026, 21:17 UTC

Ganhos

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6 de mar. de 2026, 20:50 UTC

Ganhos

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6 de mar. de 2026, 20:46 UTC

Ganhos

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6 de mar. de 2026, 20:31 UTC

Notícias Principais

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6 de mar. de 2026, 20:18 UTC

Conversa de Mercado

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6 de mar. de 2026, 20:12 UTC

Conversa de Mercado
Notícias Principais

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6 de mar. de 2026, 19:10 UTC

Conversa de Mercado
Notícias Principais

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6 de mar. de 2026, 18:54 UTC

Conversa de Mercado

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6 de mar. de 2026, 18:44 UTC

Conversa de Mercado
Notícias Principais

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6 de mar. de 2026, 18:08 UTC

Ganhos

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 de mar. de 2026, 18:04 UTC

Ganhos

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 de mar. de 2026, 18:04 UTC

Ganhos

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 de mar. de 2026, 17:49 UTC

Conversa de Mercado

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

Comparação entre Pares

Variação de preço

Laboratorios Farmaceuticos Rovi SA Previsão

Preço-alvo

By TipRanks

11.32% parte superior

Previsão para 12 meses

Média 90 EUR  11.32%

Máximo 90 EUR

Mínimo 90 EUR

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

1

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

51.1 / N/ASuporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

128 / 351 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat